Clinical Trials
Sitravatinib (MGCD516)
Sponsored by Mirati
Study 516-002:
Phase 2 study of sitravatinib in combination with nivolumab for clear cell renal cell cancer
Study 516-003:
Phase 2 study of sitravatinib in combination with a checkpoint inhibitor for urothelial carcinoma
Study 516-005:
Phase 3 study of sitravatinib in combination with nivolumab for non-small cell lung cancer (NSCLC) (SAPPHIRE)
Study 516-008:
Phase 1/1b study of sitravatinib in combination with nivolumab and ipilimumab
Sitravatinib collaborative trials are run by BeiGene and Bristol Myers Squibb, respectively.
KRAS G12C Inhibitor Adagrasib (MRTX849)
Sponsored by Mirati
Study 849-001:
Phase 1/2 study of MRTX849 in patients with cancer having a KRASG12C mutation (KRYSTAL-1)
Study 849-002:
Phase 1/2 study of MRTX849 in combination with TNO-155 in patients with cancer having a KRASG12C mutation (KRYSTAL-2)
Study 849-007:
Phase 2 study of MRTX849 in combination with pembrolizumab in NSCLC patients having a KRASG12C mutation (KRYSTAL-7)
Study 849-010:
Phase 3 study of MRTX849 with cetuximab vs chemotherapy in patients with CRC with KRASG12C mutation (KRYSTAL-10)
Study 849-012:
Phase 3 study of MRTX849 vs docetaxel in patients with NSCLC with KRASG12C mutation (KRYSTAL-12)
Study 849-014:
A Phase 1/1b study of MRTX849 in combination with BI 1701963 in patients with advanced solid tumors with KRASG12C mutation (KRYSTAL-14)
Adagrasib collaborative trials are run by Zai Lab, Sanofi, Novartis, Boehringer Ingelheim, respectively.
MTA-Cooperative PRMT5 Inhibitor (MRTX1719)
Sponsored by Mirati
Study 1719-001:
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
SOS1 (MRTX0902)
Sponsored by Mirati
Study 0902-001:
Phase 1/2 Study of MRTX0902 in Solid Tumors with Mutations in the KRAS-MAPK Pathway
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified healthcare professional.
To identify clinical trials that match your diagnosis, treatment history and location, call 1-844-893-5530 or use our online Study Locator